Allergy Immunotherapy Market, By Treatment Type (Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT) (10-30 MeV, 30 -70 MeV)), By Allergy Type (Allergic Rhinitis, Allergic Asthma, Food Allergy, Venom Allergy, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Feb 2025

Code : CMI4915

Pages :154

Formats :

Excel and PDF

Industry : Pharmaceutical

Allergy Immunotherapy Market Size and Trends

Global allergy immunotherapy market is estimated to be valued at USD 2,740.6 Mn in 2025 and is expected to reach USD 5,276.5 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2025 to 2032.

Allergy Immunotherapy Market Key Factors

To learn more about this report, Request sample copy

Global allergy immunotherapy market is expected to witness significant growth over the forecast period due to increasing prevalence of allergies such as allergy to pollen, dust, pet dander, insects bites and food allergies across the globe. Allergies have emerged as one of the major health issues affecting people of all age groups. Moreover, the development and approval of novel products such as sublingual and subcutaneous immunotherapy is expected to provide growth opportunities for market players. However, side effects associated with allergy immunotherapy and lack of awareness about available treatment options in developing countries can hamper the market growth during the forecast period.

Increasing Availability of Allergen Immunotherapy Solutions

The increasing availability of allergen immunotherapy solutions is one of the factors that is expected to drive the market growth during the forecast period. For instance, in June 2021, Stallergenes Greer, one of the global leaders in allergy immunotherapy, announced that the Alusta, subcutaneous allergen immunotherapy (SCIT) solution for different allergies involving rhinitis, conjunctivitis, rhino conjunctivitis, or asthma is now available in Spain and Italy.